• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

毛细胞白血病患者血液和骨髓细胞的流式细胞术:2-氯脱氧腺苷治疗后毛细胞和淋巴细胞亚群的表型

Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine.

作者信息

Juliusson G, Lenkei R, Liliemark J

机构信息

Department of Medicine, Huddinge Hospital, Stockholm, Sweden.

出版信息

Blood. 1994 Jun 15;83(12):3672-81.

PMID:7911341
Abstract

By flow cytometry and an extensive set of markers, we characterized leukemic cells from the blood and bone marrow of 68 symptomatic patients with hairy cell leukemia (HCL). Hairy cells identified in the large cell gate always expressed CD19, CD20, HLA-DR, CD45RA, and B-ly 7. Other markers were occasionally expressed, such as CD38, CD45RO, CD23, CD15, CD4, CD5, and CD10 (expressed on more than 20% of the hairy cells in 44%, 25%, 21%, 18%, 12%, 10%, and 5% of evaluated cases, respectively). During treatment with 2-chlorodeoxyadenosine (CdA), the median lymphocyte counts decreased from 2,000/microL to 300/microL. Flow cytometry was repeated at the nadir (n = 24) of lymphocyte counts, at 3 months (n = 46), at 6 months (n = 50), at 1 year (n = 39), and at 2 years (n = 12) after treatment. The initial decrease of CD8+ and CD20+ cells was greater than that of CD4+ and natural killer (NK) cells, leading to an increasing CD4/CD8 ratio. Median nadir values of CD4+, CD8+, CD20+, and NK cells were 128/microL, 78/microL, 10/microL, and 13/microL, respectively. The subsequent recovery was quicker for CD8+ and NK cells, leading to a normalization within 3 months, whereas CD20+ and CD4+ cells required 1 or 2 years to enter the normal range. The CD4/CD8 ratio thus decreased after the nadir and remained less than 1. CD45RA+ CD4 cells and CD45RA+/CD45RO+ double-positive cells were less affected by CdA. Activated T cells, ie, HLA-DR+ cells, rarely decreased below the normal range and often recovered with an overshoot. CD10+ cells increased in the bone marrow posttreatment as an indication of normal B-cell regeneration in 16 of 36 (44%) patients. The quick regeneration of certain lymphoid subsets might explain the lack of late infections in CdA-treated HCL patients.

摘要

通过流式细胞术和一系列广泛的标志物,我们对68例有症状的毛细胞白血病(HCL)患者血液和骨髓中的白血病细胞进行了特征分析。在大细胞门中鉴定出的毛细胞总是表达CD19、CD20、HLA-DR、CD45RA和B-ly 7。其他标志物偶尔表达,如CD38、CD45RO、CD23、CD15、CD4、CD5和CD10(分别在44%、25%、21%、18%、12%、10%和5%的评估病例中,超过20%的毛细胞表达这些标志物)。在用2-氯脱氧腺苷(CdA)治疗期间,淋巴细胞计数中位数从2000/μL降至300/μL。在淋巴细胞计数最低点(n = 24)、治疗后3个月(n = 46)、6个月(n = 50)、1年(n = 39)和2年(n = 12)时重复进行流式细胞术检测。CD8 +和CD20 +细胞的初始减少大于CD4 +和自然杀伤(NK)细胞,导致CD4/CD8比值增加。CD4 +、CD8 +、CD20 +和NK细胞的最低点中位数分别为128/μL、78/μL、10/μL和13/μL。随后,CD8 +和NK细胞的恢复更快,在3个月内恢复正常,而CD20 +和CD4 +细胞需要1年或2年才能进入正常范围。因此,CD4/CD8比值在最低点后下降并保持低于1。CD45RA + CD4细胞和CD45RA + /CD45RO +双阳性细胞受CdA的影响较小。活化的T细胞,即HLA-DR +细胞,很少降至正常范围以下,且常过度恢复。36例患者中有16例(44%)治疗后骨髓中CD10 +细胞增加,这表明正常B细胞再生。某些淋巴细胞亚群的快速再生可能解释了接受CdA治疗的HCL患者后期感染较少的原因。

相似文献

1
Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine.毛细胞白血病患者血液和骨髓细胞的流式细胞术:2-氯脱氧腺苷治疗后毛细胞和淋巴细胞亚群的表型
Blood. 1994 Jun 15;83(12):3672-81.
2
Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.毛细胞白血病患者外周血和骨髓细胞的流式细胞术:毛细胞的表型、淋巴细胞亚群及治疗后微小残留病的检测
Neoplasma. 2001;48(5):350-7.
3
Long-lasting decrease of CD4+/CD45RA+ T cells in HCL patients after 2-chlorodeoxyadenosine (2-CdA) treatment.2-氯脱氧腺苷(2-CdA)治疗后毛细胞白血病(HCL)患者CD4+/CD45RA+ T细胞持续减少。
Leukemia. 1999 Aug;13(8):1254-7. doi: 10.1038/sj.leu.2401476.
4
Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.2-氯脱氧腺苷治疗毛细胞白血病后的微小残留病
Blood Cells Mol Dis. 1995;21(2):142-51. doi: 10.1006/bcmd.1995.0016.
5
2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia.2-氯脱氧腺苷可诱导毛细胞白血病患者获得持久缓解并长期抑制CD4+淋巴细胞计数。
Blood. 1994 May 15;83(10):2906-11.
6
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].112例淋巴系统恶性疾病的骨髓免疫表型分析
Ai Zheng. 2007 Apr;26(4):418-22.
7
Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia.采用2-氯脱氧腺苷治疗毛细胞白血病后,通过骨髓活检免疫染色检测微小残留病。
Blood. 1993 Sep 15;82(6):1798-802.
8
Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland.适用于瑞士健康成年人群的外周血淋巴细胞表型参考值。
Eur J Haematol. 2004 Mar;72(3):203-12. doi: 10.1046/j.0902-4441.2003.00199.x.
9
Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up.脱氧助间型霉素治疗α-干扰素耐药的毛细胞白血病后CD4 +淋巴细胞的反应持续时间及恢复情况:7年随访
Leukemia. 1997 Jan;11(1):42-7. doi: 10.1038/sj.leu.2400513.
10
Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy-cell leukemia.22例毛细胞白血病患者经2-氯脱氧腺苷治疗后自然杀伤活性的快速恢复
Eur J Haematol. 1994 Jan;52(1):16-20. doi: 10.1111/j.1600-0609.1994.tb01279.x.

引用本文的文献

1
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia.单药利妥昔单抗是经治毛细胞白血病患者的一种有效挽救治疗方法。
Blood Adv. 2023 Nov 14;7(21):6762-6766. doi: 10.1182/bloodadvances.2023010742.
2
Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders.毛细胞白血病及其他毛细胞样疾病的新型靶向治疗
Front Oncol. 2022 Dec 22;12:1068981. doi: 10.3389/fonc.2022.1068981. eCollection 2022.
3
Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders.
毛细胞白血病(HCL)及毛细胞白血病样(HCL样)疾病的免疫表型分析
Cancers (Basel). 2022 Feb 18;14(4):1050. doi: 10.3390/cancers14041050.
4
Dissection of the bone marrow microenvironment in hairy cell leukaemia identifies prognostic tumour and immune related biomarkers.对毛细胞白血病骨髓微环境的剖析确定了预后相关的肿瘤和免疫生物标志物。
Sci Rep. 2021 Sep 24;11(1):19056. doi: 10.1038/s41598-021-98536-1.
5
Haematological profile of 21 patients with hairy cell leukaemia in a tertiary care centre of north India.印度北部一家三级医疗中心21例毛细胞白血病患者的血液学特征
Indian J Med Res. 2015 Oct;142(4):426-9. doi: 10.4103/0971-5916.169204.
6
Hairy cell leukemia: update and current therapeutic approach.毛细胞白血病:最新进展与当前治疗方法
Curr Opin Hematol. 2015 Jul;22(4):355-61. doi: 10.1097/MOH.0000000000000154.
7
Immunophenotypic aberrancy of a case of hairy cell leukemia.一例毛细胞白血病的免疫表型异常
Indian J Hematol Blood Transfus. 2015 Jun;31(2):292-4. doi: 10.1007/s12288-014-0433-x. Epub 2014 Jul 20.
8
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.毛细胞白血病中 BRAFV600E 突变的造血干细胞起源。
Sci Transl Med. 2014 May 28;6(238):238ra71. doi: 10.1126/scitranslmed.3008004.
9
Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.区分毛细胞白血病变异型与毛细胞白血病:诊断标准的制定与验证。
Leuk Res. 2013 Apr;37(4):401-409. doi: 10.1016/j.leukres.2012.11.021. Epub 2013 Jan 22.
10
Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.新旧嘌呤核苷类似物在淋巴增生性疾病治疗中的现状
Molecules. 2009 Mar 23;14(3):1183-226. doi: 10.3390/molecules14031183.